In-house members
10
Total footprint
15,000 sq ft
The incubator where it all started, our St Philips incubator is typically home to earlier-stage Deep Tech teams of around 10-20 and has been the launchpad for many success stories — from startups scaling to bigger facilities to game-changing company exits.
Work alongside pioneering startups tackling global issues — from next-generation battery materials and better diabetes treatments to quantum-enabled cameras that track greenhouse gas leaks.
Our St Philips incubator (previously Unit DX) opened in 2017 to improve access to lab space and facilities for scientific companies in Bristol.
Just a 10-minute walk from Bristol Temple Meads train station, the space combines purpose-built laboratories, flexible offices and cutting-edge instrumentation.
Rent an entire lab or just a lab bench; have a private office or share one — and access our platform of support, providing opportunities to attend workshops and events, connect with other founders, and find a mentor.
Get in touch if you are after shared or private lab space at St Philips or browse our other sites for more private lab space.
Travel between locations is measured in walking distance
Albert Rd
0.5 miles / 11 min
0.7 miles / 15 min
Scarlet Therapeutics is developing a proprietary platform that generates novel red blood cell-based therapeutics (tRBCs) to treat a wide range of diseases. Its technologies are underpinned by learnings from decades of research including the groundbreaking RESTORE clinical study run by NHS Blood and Transplant and the University of Bristol, investigating transfusion of lab-grown blood into patients. By generating tRBCs with high levels of therapeutic proteins from cell lines rather than from donated stem cells, Scarlet Therapeutics aims to address significant efficacy and manufacturing issues faced in the field.
Extracellular is developing cell culture technologies to use the cell samples of living animals and plants to create sustainable alternatives to commercial products in the cosmetic, material and food industries. As a bioprocessing and manufacturing partner, it provides solutions from cell-line and scale-up development to facilitating routes to market, supporting other biotech companies seeking to develop greener consumer products such as cultivated meat, dairy products, leather, cotton and active ingredients for cosmetics.
EnsiliTech is improving the shelf-life and global accessibility of vaccines and other biological therapeutics by combatting cold chain transport and storage issues. Its novel ensilication technology, designed for both existing and new biopharmaceutical formulations, encases thermally unstable biomolecules within silica nanoshells to prevent environmental degradation. This eliminates the need for cold chain requirements that are expensive, prone to failure and generate significant carbon dioxide emissions.
Triple Bio is developing a new technology platform to boost milk yields and reduce methane in cattle. Its next-generation solution, RumeNRG™, uses advanced lipid technology inspired by nature to rebalance the rumen microbiome. It overcomes the limitations of current methane inhibitors by offering dual efficacy: enhanced profitability for farmers alongside a significant sustainability impact.
NuNano is advancing the field of atomic force microscopy with high-precision probes for nanometer-scale imaging. Its proprietary microfabrication processes produce reliable, high-quality probes with market-leading dimensional tolerances. It also provides dedicated support to its customers, from probe selection to storage, for a seamless user experience.
Lifecare is committed to improving the lives of people and pets with diabetes. It is developing the next-generation of miniaturized and implantable nanobiosensors for correct and continuous monitoring of glucose and other biomarkers to the market. The company’s spin-off entity Lifecare Chemistry Ltd was founded to enhance research collaboration and secure ownership of its improved analyte-specific chemical receptor developments.
Epinal is revolutionising the detection and prevention of narcotic-impaired behaviour for safer roads, flights and workplaces. Utilising AI and novel biotechnology that mimics natural sensory mechanisms, it’s developing a handheld breathalyser that generates rapid results with extreme sensitivity and selectivity.
GenomeKey is transforming how healthcare clinicians diagnose and treat infections like sepsis to improve patient outcomes. Using cutting-edge machine learning and DNA sequencing, the company is developing a next-generation diagnostic device to identify bacterial genomes and determine their antimicrobial susceptibility directly from patient blood in just a few hours, rather than days. This enables clinicians to prescribe the right antibiotics for patients with much more efficiency and accuracy, reducing costs, minimising unnecessary antibiotic use and ultimately saving millions of lives from the world’s leading cause of death.
CellVoyant is accelerating the development of novel stem cell-based therapies for chronic diseases. Its technology uses AI-first live cell imaging to predict and optimise stem cell differentiation, enable advanced cell analytics and ultimately unlock the controllable manufacturing of any cell and tissue in the body at scale. Built on foundational research at the University of Bristol, CellVoyant works at the intersection of cell biology, computing, engineering and machine learning to carry out its mission.
